|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||1.5620 - 1.6160|
|52 Week Range||1.4120 - 3.0500|
|Beta (3Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.63|
In December 2018, Mauna Kea Technologies SA (EPA:MKEA) released its most recent earnings announcement, which signalled...
If you own shares in Mauna Kea Technologies SA (EPA:MKEA) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers...
Mauna Kea Technologies (MKEA.PA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of the Cellvizio AQ-Flex™ 19 Confocal Miniprobe™ through existing bronchoscopes, transbronchial needles and other bronchoscopic accessories. “Our pioneering team has demonstrated that real-time imaging and identification of benign and malignant cellular structures inside pulmonary nodules and lymph nodes with needle-based Confocal Laser Endomicroscopy is not only feasible but highly reproducible.” said Pr. The Cellvizio AQ-Flex™ 19 Confocal Miniprobe™ can be used through the working channel of existing navigation products to provide direct “through the needle” visualization inside peripheral lesions.
Mauna Kea Technologies (MKEA.PA) (MKEAF) (MKEA.NX) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced a mutual decision to terminate the development and distribution agreements with Cook Medical. “Mauna Kea announced a change in commercial strategy in the Fall of 2015 which included moving to an expanded marketing system to commercialize Cellvizio in new clinical applications through strategic sales partnerships with established medical device companies,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “In December 2015, the Company signed the first of these strategic partnerships when it announced a multi-year worldwide exclusive marketing partnership agreement with Cook Medical to use the Cellvizio platform in urological applications.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Mauna Kea Technologies SARead More...
Two important questions to ask before you buy Mauna Kea Technologies SA (EPA:MKEA) is, how it makes money and how it spends its cash. What is left after investment, determines Read More...
While small-cap stocks, such as Mauna Kea Technologies SA (EPA:MKEA) with its market cap of €73m, are popular for their explosive growth, investors should also be aware of their balance Read More...
Mauna Kea Technologies (MKEA.PA) (MKEAF) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced results from the large, prospective, multi-center validation CONTACT 2 study that met its primary and secondary endpoints, demonstrating significantly higher diagnostic performance of nCLE with Cellvizio® compared to standard of care methods in patients with pancreatic cyst lesions (PCLs). The findings were published in the article “Needle-based confocal laser endomicroscopy of pancreatic cystic lesions: a prospective multicenter validation study in patients with definite diagnosis” in the peer-reviewed publication Endoscopy.
If you own shares in Mauna Kea Technologies SA (EPA:MKEA) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a Read More...
Results of breakthrough PERSEE trial involving live transmission and robotized use of Cellvizio confocal miniprobe published online in Surgical Endoscopy